Background. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are now major threats in areas of South Africa with a high prevalence of TB and human immunodeficiency virus (HIV) infection. The role of exogenous reinfection as a cause of MDR and XDR TB in these settings has not been determined.
Multidrug-resistant tuberculosis (MDR TB) is a major public health problem worldwide, afflicting an estimated 489,000 people annually [1] . The prevalence of MDR TB has been estimated to be low in sub-Saharan Africa; however, surveillance for drug resistance has been limited [1] . Recent studies have indicated higherthan-anticipated rates of MDR TB in several settings with a high prevalence of HIV infection [2] [3] [4] [5] [6] [7] , as well as the emergence of extensively drug-resistant (XDR) TB. Drug resistance may result from 1 of the following 2 mechanisms: inadequate therapy that enables selection of drug-resistant organisms (acquired resistance) or infection with a drugresistant TB strain (primary resistance). Although acquired resistance is presumed to be responsible for the majority of cases of MDR or XDR TB, this may be a misleading assumption, particularly in HIV-infected patients who are more prone to recurrence due to exogenous reinfection [8] . The high prevalence of HIV infection (19% of the adult population) and the high TB incidence (940 cases per 100,000 population) in South Africa [9, 10] , combined with the lack of airborne infection control practices, could enhance the possibility that reinfection with drug-resistant strains may become a significant factor in the development of drug-resistant TB.
Distinguishing between acquired and primary resistance is important for creating a strategy to address the expanding drugresistant TB epidemic. If the vast majority of cases of MDR or XDR TB develop as a result of acquired resistance, emphasis must be placed on strengthening directly observed treatment short course (DOTS) TB programs and improving treatment completion rates. If, however, primary resistance is a major factor, the creation and implementation of infection control programs must be added as a critical component of the control strategy, in addition to strengthening TB programs, to curb the ongoing transmission of drug-resistant strains.
In the first published report of XDR TB in South Africa, a significant proportion of cases were believed to be the result of primary transmission of resistant strains [11] because the subjects had never been previously treated for TB [3] . Even among patients previously treated for TB, however, we observed that most subsequent TB episodes were caused by organisms resistant to second-line TB medications, despite the patients' having received only first-line TB therapy [12] . This observation prompted us to examine the role of primary resistance due to exogenous reinfection in the development of MDR or XDR TB.
In this study, we sought to determine the cause of infections due to organisms resistant to an increasing number of drugs among a series of patients receiving TB therapy in a high HIV prevalence, rural district hospital in KwaZulu-Natal, South Africa. We used genotyping of pretreatment and subsequent Mycobacterium tuberculosis isolates to distinguish between exogenous reinfection and acquired drug resistance [8, [13] [14] [15] [16] [17] [18] .
METHODS

Setting.
The study was conducted in the Msinga subdistrict of KwaZulu-Natal, South Africa, a 2000 km 2 rural area, home to 250,000 traditional Zulu people. A 355-bed government district hospital provides health care for this population. It consists of congregate wards, ranging from 40 to 70 beds, for medicine, surgery, tuberculosis, pediatrics, obstetrics, and psychiatry. A government-sponsored TB DOTS program treats approximately 2000 TB cases per year. The annual incidence of TB is greater than 1000 per 100,000 population, and more than 80% of cases are coinfected with HIV [6] . Patients diagnosed with TB are provided with a 2-month intensive phase of treatment with isoniazid, rifampicin, ethambutol, and pyrazinamide, followed by a 4-month continuation phase of treatment with isoniazid and rifampicin. Directly observed therapy (DOT) is provided on-site or at the patient's home 5 days per week. Patients are followed up with repeat sputum smears or cultures at 2 months and 6 months, as well as in cases of deterioration or lack of clinical response.
At the time of this study, patients who were diagnosed with MDR or XDR TB received a standardized second-line treatment regimen consisting of a 4-month intensive phase of treatment with kanamycin, ofloxacin, ethionamide, pyrazinamide, and, depending on ethambutol susceptibility testing results, either ethambutol or terizidone-cycloserine, plus a continuation phase of 12-18 months of treatment with ofloxacin, ethionamide, and ethambutol or terizidone-cycloserine. Treatment was provided by a centralized, provincial drug-resistant TB program in Durban, which required inpatient admission for the 4-month intensive phase followed by outpatient treatment with monthly follow-up for the continuation phase.
Study population. Patients were screened for this study if they developed MDR or XDR TB after initially being diagnosed and treated for a less drug-resistant form of TB (e.g., if MDR or XDR TB developed after an initial infection with drugsusceptible TB, or XDR TB developed after MDR TB). Patients were included if they had 2 positive culture results that included drug susceptibility testing (DST) results obtained Ͼ30 days apart and if both the initial isolate (obtained at the time of treatment initiation) and follow-up isolates were available for genotyping.
Hospital medical records were reviewed for all patients. The data collected included mortality, HIV infection status, CD4 cell count, use of antiretroviral drugs, TB treatment history, and hospitalization history. We used these data to describe the clinical and treatment characteristics of patients affected by primary drug resistance due to exogenous reinfection with a drugresistant strain of TB.
Laboratory methods. Specimens were transported to the provincial mycobacteriology laboratory at Inkosi Albert Luthuli Central Hospital in Durban. Specimens were digested and decontaminated by the N-acetyl-l-cysteine-sodium hydroxide method and inoculated onto Middlebrook 7H11 agar and mycobacterial growth indicator tubes. Susceptibility testing for isoniazid (H), rifampicin (R), ethambutol (E), streptomycin (S), ciprofloxacin (Cx), and kanamycin (Km) was performed on Middlebrook 7H10 agar, as described elsewhere [3] , by using the 1% proportional method. Isolates were classified in the following drug-resistance groups: (1) drug-susceptible TB, which was susceptible to H or R or both, irrespective of susceptibility to other drugs; (2) MDR TB, which was resistant to at least H and R, but not both Cx and Km; or (3) XDR TB, which was resistant to at least H, R, Cx, and Km [19] .
Spoligotyping was performed on all available isolates from patients who developed MDR or XDR TB. Spoligotyping patterns were analyzed and classified by shared type (ST) in accordance with the Fourth International Spoligotyping Database [20] . Patients whose initial and follow-up isolates showed differences in ST were considered cases of exogenous reinfection with a resistant organism. Patients whose initial and follow-up isolates had the same ST were considered possible cases of acquired drug resistance.
Bivariate analyses compared clinical characteristics of patients for whom isolates were available for spoligotyping with those for whom isolates were not available. The Wilcoxon test was used to compare medians, and Fisher's exact test was used for dichotomous and nominal data. The study was approved by the institutional review boards of the University of KwaZulu-Natal, Yale University, and Albert Einstein College of Medicine.
RESULTS
From June 2005 through June 2006, we identified 23 patients who developed MDR or XDR TB after initially being diagnosed and treated for a less-resistant form of TB. Table 1 shows the changes in the drug resistance patterns and spoligotypes of isolates recovered from these 23 eligible patients. Nine patients (39%) initially had a drug-susceptible isolate recovered, fol- lowed by an MDR isolate; 10 (43%) initially had a drugsusceptible isolate recovered, followed by an XDR isolate; 3 (13%) initially had a drug-susceptible isolate recovered, followed by both an MDR and an XDR isolate; and 1 (4%) initially had an MDR isolate recovered, followed by an XDR isolate.
Spoligotypes for 2 or more isolates were available for 17 (74%) of the 23 patients. Patients with and without isolates available for spoligotyping did not differ significantly in their demographic or clinical characteristics (table 2) . For all of these 17 patients, spoligotype patterns were different between the initial and follow-up isolates (table 1) . Thus, all 17 patients developed MDR or XDR TB as a result of primary resistance due to exogenous reinfection with drug-resistant strains. Among these 17 patients, 20 documented episodes of reinfection were observed. Thirteen patients (patients 1-5 and 10 -17; table 1) experienced a single episode of reinfection with 1 strain and thus with a single DST pattern, 3 patients (20, 21, and 23) experienced a single episode that involved 2 strains with differing DST patterns, and 1 patient (22) had 3 episodes of reinfection with different strains during each episode. The 4 spoligotype patterns for isolates recovered from patient 22 are shown in figure 1.
Genotypes. Of the 17 patients with initial isolates available, 2 were infected with 2 different genotypes (patients 1 and 10; figure 2A ). Of the 12 XDR TB strains that caused reinfection, 10 (83%) were genotype ST 60, and 2 (17%) were genotype ST 53 (figure 2B).
Although the majority of MDR TB and XDR TB reinfections were caused by genotypes ST 34 and ST 60, respectively, the reinfecting strains differed in their DST patterns (table 3) . Drugsusceptible isolates of ST 34 and ST 60 were also seen among the initial patient isolates (patients 20 and 1, respectively; table 1).
Clinical characteristics of patients affected by primary resistance due to exogenous reinfection. HIV serostatus was known for 15 of the 17 patients affected by primary resistance, and all were HIV-infected (table 2). CD4 cell counts were available for 12 patients; the median CD4 count was 86.5 cells/mm 3 (range, 13-357 cells/mm 3 ). Three of 15 patients had received antiretroviral therapy; all 3 initiated therapy in the period between the time the initial and follow-up sputum specimens were obtained. The median number of days between collection of the initial and second sputum specimen was 154 days (range, 68 -321 days; table 1). All 17 patients (100%) were hospitalized either at the time TB treatment was initiated or between the initiation of treatment and the collection of a follow-up sputum specimen. The median number of days in the hospital was 25.5 days (IQR, 7-38 days). Three patients (18%) had previously been treated for TB.
Fifteen (88%) of 17 patients died. The date of death was available for 12 patients. Median survival time from after collection of the follow-up sputum specimen was 14 days (range, 3-36 days). Of the 2 patients who survived, both had XDR TB and received second-line drugs, and 1 received antiretroviral therapy.
DISCUSSION
In this study, we sought to characterize the role of exogenous reinfection with drug-resistant TB strains (primary resistance) versus the acquisition of resistance as a result of inadequate drug therapy (acquired resistance) in the development of MDR or XDR TB in an area with high prevalences of both HIV infection and drug-resistant TB. We used spoligotyping to compare TB isolates obtained at the time of treatment initiation with follow-up isolates that were identified as MDR or XDR TB. We found that all patients who developed MDR or XDR TB did so as a result of reinfection rather than as a result of acquired resistance. To our knowledge, this is the first study to document exogenous reinfection as the cause of MDR and XDR TB in an area with a high prevalence of HIV infection and may provide important insights into the rapidly expanding drug-resistant TB epidemic in South Africa. It also adds to the body of literature demonstrating the role of exogenous reinfection in the development of drug-susceptible, MDR, and XDR TB worldwide [8, 14, 16 -18, 22-27] .
The emergence of MDR and XDR TB in areas of sub-Saharan Africa with high prevalences of HIV infection and TB has been described as "the perfect storm" [28] , threatening to overwhelm public health programs and undermine the success of antiretroviral therapy rollouts [29] . In our initial study of XDR TB, the majority of cases were believed to have been the result of primary drug resistance because most patients had not been previously treated for TB, and the isolates recovered from these patients were genetically similar to those recovered from other patients [3] . Despite this, responses to XDR TB in this setting have mainly focused on improving treatment adherence to prevent acquired resistance [30, 31] . Although treatment adherence should remain central to TB control, this strategy alone may be insufficient to blunt the rise of MDR and XDR TB if the transmission of drug-resistant strains is a significant factor in the development of cases. Our present study confirms the major role of primary drug resistance in the development of MDR and XDR TB in this setting where the prevalence of HIV infection is high. Aggressive efforts to reduce transmission by implementing available infection control strategies is now critical to blunt the further spread of this epidemic [32, 33] .
The high rate of HIV coinfection and hospitalization in this study underscores the vulnerability of HIV-infected patients to reinfection when exposed in the hospital setting [8, 17, 22] . When combined with a lack of individual respiratory isolation and a 4 -6 week waiting period for mycobacterial culture results and DST results, hospital admissions place HIV-coinfected patients at very high risk for infection with MDR or XDR TB [34] . This risk was recently quantified in a study that showed that more than one-third of patients exposed to an infectious source in crowded, poorly ventilated hospitals would become infected within 24 h [34] .
The consequences of reinfection with MDR or XDR TB cannot be overestimated because mortality among reinfected patients was 88% (15 of 17), and median survival time was only 14 days. This time period is substantially shorter than the 4 -6 weeks required for conventional culture and drug susceptibility testing. This rapid mortality underscores the need for preventing reinfection with MDR and XDR TB by instituting infection control measures because prompt diagnosis and treatment with currently available techniques would not have been sufficient to save these patients.
A single spoligotype (ST 34) was responsible for the majority of MDR TB reinfections, while another (ST 60) was responsible for nearly all of XDR TB reinfections. It is unclear whether these represent single-point sources or whether they belong to common endemic TB strain families circulating in this region. ST 60 is likely the same as the F15/LAM4/KZN strain, previously described as endemic in KwaZulu-Natal [35] . To further elucidate the molecular epidemiology of these spoligotypes, studies applying additional genotyping methods, including IS6110 restriction fragment length polymorphism (RFLP), are needed.
Our findings are subject to several caveats. First, although cross-contamination could explain a change in DST and spoligotype for any patient, it is unlikely because the majority of patients died soon after their MDR or XDR TB isolate was collected, suggesting a true change in clinical status. Next, mixed infection with both drug-susceptible and MDR or XDR TB strains at the time of initial TB diagnosis is an alternative explanation to our findings, since mixed infections due to 2 strains may be present in 10%-20% of cases [36 -38] . Regardless, the transmission of MDR and XDR TB strains, not acquired resistance, would have caused those mixed infections, because most patients had not previously received TB treatment. Finally, although spoligotyping is not as discriminating as IS6110 RFLP in distinguishing between TB strains which are closely related, strains with differing spoligotypes are highly unlikely to be the same [39] . NOTE. Data are no. of isolates. Initial isolates were obtained at the time of treatment initiation. Although ST 34 and ST 60 caused the majority of reinfections with multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB, respectively, a diversity of drug-susceptibility patterns were seen among the various isolates of these strains. Fully susceptible isolates of ST 34 and ST 60 were also found among the initial patient isolates. Among the reinfecting MDR TB isolates, ST 34 isolates were found to have 2 different drug susceptibility patterns, whereas ST 60 isolates had 5 different drug susceptibly patterns in both the MDR and XDR TB categories among the reinfecting strains. Cx, ciprofloxacin; E, ethambutol; H, isoniazid; Km, kanamycin; R, rifampicin; S, streptomycin.
Exogenous reinfection with drug-resistant strains of M. tuberculosis is an important mechanism by which MDR or XDR TB develops in settings with a high prevalence of HIV infection. This mode of developing TB drug resistance may be a major factor in the rapid rise in the number of MDR and XDR TB cases in South Africa. The high prevalence of MDR and XDR TB, combined with extremely high rates of HIV coinfection and near-absent airborne infection control in health care facilities, represent a pernicious triad facilitating transmission of drug-resistant TB. Urgent measures are needed to prevent the transmission of MDR and XDR TB in this setting.
